Hotovosť na akciu spoločnosti Neovacs S.A
Aká je hodnota metriky Hotovosť na akciu spoločnosti Neovacs S.A?
Hodnota metriky Hotovosť na akciu spoločnosti Neovacs S.A. je 0.02
Aká je definícia metriky Hotovosť na akciu?
Hotovosť na akciu (Cash per share) je pomer ihneď dostupných peňazí prístupných na výdaj a vydaných akcií spoločnosti.
Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.
When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.
Hotovosť na akciu spoločností v sektore Health Care sektor na EURONEXT v porovnaní so spoločnosťou Neovacs S.A
Čomu sa venuje spoločnosť Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Firmy s metrikou hotovosť na akciu podobnou spoločnosti Neovacs S.A
- Hodnota metriky Hotovosť na akciu spoločnosti ELL Environmental je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti Jervois Mining je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti Graphite One je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti Juniper II je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti AMCI Acquisition je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti Newborn Acquisition je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti Neovacs S.A je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti Saville Resources je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti Coolpad je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti Mexican Gold Mining je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti Volt je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti McLeod Russel India je 0.02
- Hodnota metriky Hotovosť na akciu spoločnosti Hao Tian International Construction Investment je 0.02